Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma.

[1]  J. Kirkwood,et al.  Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial. , 1984, Cancer treatment reports.

[2]  E. Hersh,et al.  Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon. , 1983, Journal of the National Cancer Institute.

[3]  N. Holbrook,et al.  Direct suppression of natural killer activity in human peripheral blood leukocyte cultures by glucocorticoids and its modulation by interferon. , 1983, Cancer research.

[4]  L. Juliano,et al.  Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. , 1983, Journal of immunology.

[5]  P. Hersey,et al.  Expression of Thy‐1 antigen on human melanoma cells , 1983, International journal of cancer.

[6]  J. Quesada,et al.  Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in a intermittent schedule in cancer patients. , 1983, Journal of the National Cancer Institute.

[7]  F. Belardelli,et al.  Antitumor effects of interferon in mice injected with interferon‐sensitive and interferon‐resistant friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously , 1983, International journal of cancer.

[8]  R. Suzuki,et al.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). I. Proliferative response and establishment of cloned cells. , 1983, Journal of immunology.

[9]  G. Westbury,et al.  Evaluation of human lymphoblastoid interferon in advanced malignant melanoma , 1983, Cancer.

[10]  R. Benjamin,et al.  The natural history of resectable metastatic melanoma (Stage IVA Melanoma) , 1982, Cancer.

[11]  S. Rosenberg,et al.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes , 1982, The Journal of experimental medicine.

[12]  T. Merigan,et al.  Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. , 1982, Annals of internal medicine.

[13]  D. Morton,et al.  Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell population. , 1982, Journal of the National Cancer Institute.

[14]  H. Pross,et al.  Studies of human natural killer cells. I. in vivo parameters affecting normal cytotoxic function , 1982, International journal of cancer.

[15]  P. Hersey,et al.  Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2 , 1981, International journal of cancer.

[16]  S. Argov,et al.  Disappearance of the NK effect after explantation of lymphocytes and generation of similar nonspecific cytotoxicity correlated to the level of blastogenesis in activated cultures. , 1980, Journal of immunology.

[17]  T. Merigan,et al.  Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. Haynes,et al.  The differential effect of in vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus-derived lymphocytes. , 1978, The Journal of clinical investigation.

[19]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[20]  I. Kimber.  Natural killer cells. , 1985, Medical laboratory sciences.

[21]  J. Spinelli,et al.  Effect of lymphoblastoid interferon on lymphocyte subsets in cancer patients. , 1983, Journal of biological response modifiers.

[22]  P. Hersey,et al.  No evidence for an association between natural killer cell activity and prognosis in melanoma patients. , 1983, Natural immunity and cell growth regulation.

[23]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[24]  H. Blomgren,et al.  Lymphokine production by PHA-stimulated human lymphocytes is enhanced by interferon. , 1981, International archives of allergy and applied immunology.